Company intelligence / Profile preview

Senti Tech

South San Francisco, California, United Statessenti.care ↗

Ownership: Private
Employees: ~34
Development stage: Commercial

Overview

Initial data from the Phase 1 trial of SENTI-202 in relapsed/refractory AML showed MRD-negative complete remissions in 2 out of 3 patients at the first dose level. Dose finding is ongoing. SENTI Biosciences has also received an $8 million grant from CIRM to support further development.

Therapeutic areas: Oncology
Modalities: Cell therapyChimeric antigen receptor natural killer cell therapyGene circuit-enabled therapiesGene Therapy
Industry: Biotech

Partnerships

Spark TherapeuticsBlueRock TherapeuticsCelest BiopharmaLeaps by BayerNew Enterprise AssociatesThe Carlyle Group

Beyond the preview

Go deeper on Senti Tech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senti Tech.

Explore the full profile